#begin document (en_5171.txt); part 000
en_5171.txt	0	0	Race-Based	JJ	(TOP(INTJ*	-	-	-	-	*	-
en_5171.txt	0	1	Medicine	NN	*	-	-	-	-	*	-
en_5171.txt	0	2	?	.	*))	-	-	-	-	*	-

en_5171.txt	0	0	PALO	NNP	(TOP(X*	-	-	-	-	*	-
en_5171.txt	0	1	ALTO	NNP	*	-	-	-	-	*	-
en_5171.txt	0	2	–	SYM	(X*)	-	-	-	-	*	-
en_5171.txt	0	3	Race	CC	(X*	-	-	-	-	*	-
en_5171.txt	0	4	can	MD	(VP*	-	-	-	-	*	-
en_5171.txt	0	5	undoubtedly	RB	(ADVP*)	-	-	-	-	*	-
en_5171.txt	0	6	be	VB	(VP*	-	-	-	-	*	-
en_5171.txt	0	7	a	DT	(NP*	-	-	-	-	*	-
en_5171.txt	0	8	tricky	JJ	*	-	-	-	-	*	-
en_5171.txt	0	9	subject	NN	*)	-	-	-	-	*	-
en_5171.txt	0	10	,	,	*	-	-	-	-	*	-
en_5171.txt	0	11	with	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	12	any	DT	(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	13	suggestion	NN	*)	-	-	-	-	*	-
en_5171.txt	0	14	of	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	15	genetic	JJ	(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	16	differences	NNS	*)	-	-	-	-	*	-
en_5171.txt	0	17	among	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	18	racial	JJ	(NP*	-	-	-	-	*	-
en_5171.txt	0	19	groups	NNS	*))))))))	-	-	-	-	*	-
en_5171.txt	0	20	–	SYM	(X*)	-	-	-	-	*	-
en_5171.txt	0	21	beyond	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	22	superficial	JJ	(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	23	characteristics	NNS	*)	-	-	-	-	*	-
en_5171.txt	0	24	like	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	25	skin	NN	(NP*	-	-	-	-	*	-
en_5171.txt	0	26	color	NN	*)))))	-	-	-	-	*	-
en_5171.txt	0	27	–	SYM	(X(X*)	-	-	-	-	*	-
en_5171.txt	0	28	potentially	RB	(NP(NP(NP(ADJP*	-	-	-	-	*	-
en_5171.txt	0	29	invoking	VBG	*)	-	-	-	-	*	-
en_5171.txt	0	30	memories	NNS	*)	-	-	-	-	*	-
en_5171.txt	0	31	of	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	32	the	DT	(NP*	-	-	-	-	*	(0
en_5171.txt	0	33	nineteenth-century	JJ	*	-	-	-	-	*	-
en_5171.txt	0	34	eugenics	NNS	*	-	-	-	-	*	-
en_5171.txt	0	35	movement	NN	*)))	-	-	-	-	*	0)
en_5171.txt	0	36	and	CC	*	-	-	-	-	*	-
en_5171.txt	0	37	its	PRP$	(NP(NP*	-	-	-	-	*	(0)
en_5171.txt	0	38	eventual	JJ	*	-	-	-	-	*	-
en_5171.txt	0	39	role	NN	*)	-	-	-	-	*	-
en_5171.txt	0	40	in	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	41	Nazi	JJ	(NP*	-	-	-	-	*	-
en_5171.txt	0	42	ideology	NN	*)))))	-	-	-	-	*	-
en_5171.txt	0	43	.	.	*))	-	-	-	-	*	-

en_5171.txt	0	0	Now	RB	(TOP(S(ADVP*)	-	-	-	-	*	-
en_5171.txt	0	1	,	,	*	-	-	-	-	*	-
en_5171.txt	0	2	with	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	3	drug	NN	(S(NP*	-	-	-	-	*	-
en_5171.txt	0	4	companies	NNS	*)	-	-	-	-	*	-
en_5171.txt	0	5	increasingly	RB	(ADVP*)	-	-	-	-	*	-
en_5171.txt	0	6	seeking	VBG	(VP*	-	-	-	-	*	-
en_5171.txt	0	7	to	TO	(S(VP*	-	-	-	-	*	-
en_5171.txt	0	8	develop	VB	(VP*	-	-	-	-	*	-
en_5171.txt	0	9	medications	NNS	(NP(NP*)	-	-	-	-	*	-
en_5171.txt	0	10	that	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_5171.txt	0	11	target	VBP	(S(VP*	-	-	-	-	*	-
en_5171.txt	0	12	particular	JJ	(NP*	-	-	-	-	*	-
en_5171.txt	0	13	racial	JJ	*	-	-	-	-	*	-
en_5171.txt	0	14	groups	NNS	*)))))))))))	-	-	-	-	*	-
en_5171.txt	0	15	,	,	*	-	-	-	-	*	-
en_5171.txt	0	16	the	DT	(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	17	long-taboo	JJ	*	-	-	-	-	*	-
en_5171.txt	0	18	subject	NN	*)	-	-	-	-	*	-
en_5171.txt	0	19	of	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	20	racial	JJ	(NP*	-	-	-	-	*	-
en_5171.txt	0	21	genetics	NNS	*)))	-	-	-	-	*	-
en_5171.txt	0	22	has	VBZ	(VP*	-	-	-	-	*	-
en_5171.txt	0	23	reemerged	VBN	(VP*))	-	-	-	-	*	-
en_5171.txt	0	24	.	.	*))	-	-	-	-	*	-

en_5171.txt	0	0	Much	JJ	(TOP(S(NP(NP*)	-	-	-	-	*	-
en_5171.txt	0	1	of	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	2	the	DT	(NP*	-	-	-	-	*	-
en_5171.txt	0	3	current	JJ	*	-	-	-	-	*	-
en_5171.txt	0	4	debate	NN	*)))	-	-	-	-	*	-
en_5171.txt	0	5	centers	VBZ	(VP*	-	-	-	-	*	-
en_5171.txt	0	6	on	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	7	whether	IN	(SBAR(SBAR*	-	-	-	-	*	-
en_5171.txt	0	8	race	NN	(S(NP*)	-	-	-	-	*	-
en_5171.txt	0	9	should	MD	(VP*	-	-	-	-	*	-
en_5171.txt	0	10	be	VB	(VP*	-	-	-	-	*	-
en_5171.txt	0	11	a	DT	(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	12	criterion	NN	*)	-	-	-	-	*	-
en_5171.txt	0	13	for	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	14	inclusion	NN	(NP(NP(NP*)	-	-	-	-	*	-
en_5171.txt	0	15	in	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	16	clinical	JJ	(NP*	-	-	-	-	*	-
en_5171.txt	0	17	trials	NNS	*)))	-	-	-	-	*	-
en_5171.txt	0	18	–	SYM	(X*))))))))	-	-	-	-	*	-
en_5171.txt	0	19	and	CC	*	-	-	-	-	*	-
en_5171.txt	0	20	,	,	(PRN*	-	-	-	-	*	-
en_5171.txt	0	21	by	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	22	extension	NN	(NP*))	-	-	-	-	*	-
en_5171.txt	0	23	,	,	*)	-	-	-	-	*	-
en_5171.txt	0	24	whether	IN	(SBAR*	-	-	-	-	*	-
en_5171.txt	0	25	drug	NN	(S(NP*	-	-	-	-	*	-
en_5171.txt	0	26	labeling	NN	*)	-	-	-	-	*	-
en_5171.txt	0	27	should	MD	(VP*	-	-	-	-	*	-
en_5171.txt	0	28	mention	VB	(VP*	-	-	-	-	*	-
en_5171.txt	0	29	race	NN	(NP*)	-	-	-	-	*	-
en_5171.txt	0	30	specifically	RB	(ADVP*))))))))	-	-	-	-	*	-
en_5171.txt	0	31	.	.	*))	-	-	-	-	*	-

en_5171.txt	0	0	Although	IN	(TOP(S(S(SBAR*	-	-	-	-	*	-
en_5171.txt	0	1	the	DT	(S(NP*	-	-	-	-	*	-
en_5171.txt	0	2	issues	NNS	*)	-	-	-	-	*	-
en_5171.txt	0	3	are	VBP	(VP*	-	-	-	-	*	-
en_5171.txt	0	4	complicated	VBN	(VP*))))	-	-	-	-	*	-
en_5171.txt	0	5	,	,	*	-	-	-	-	*	-
en_5171.txt	0	6	the	DT	(NP*	-	-	-	-	*	-
en_5171.txt	0	7	solution	NN	*)	-	-	-	-	*	-
en_5171.txt	0	8	is	VBZ	(VP*	-	-	-	-	*	-
en_5171.txt	0	9	simple	JJ	(ADJP*)))	-	-	-	-	*	-
en_5171.txt	0	10	:	:	*	-	-	-	-	*	-
en_5171.txt	0	11	follow	VB	(S(VP*	-	-	-	-	*	-
en_5171.txt	0	12	the	DT	(NP*	-	-	-	-	*	(1
en_5171.txt	0	13	data	NNS	*)))	-	-	-	-	*	1)
en_5171.txt	0	14	.	.	*))	-	-	-	-	*	-

en_5171.txt	0	0	In	IN	(TOP(S(PP*	-	-	-	-	*	-
en_5171.txt	0	1	fact	NN	(NP*))	-	-	-	-	*	-
en_5171.txt	0	2	,	,	*	-	-	-	-	*	-
en_5171.txt	0	3	clinical	JJ	(NP*	-	-	-	-	*	-
en_5171.txt	0	4	trials	NNS	*)	-	-	-	-	*	-
en_5171.txt	0	5	are	VBP	(VP*	-	-	-	-	*	-
en_5171.txt	0	6	not	RB	*	-	-	-	-	*	-
en_5171.txt	0	7	intended	VBN	(VP*	-	-	-	-	*	-
en_5171.txt	0	8	to	TO	(S(VP*	-	-	-	-	*	-
en_5171.txt	0	9	demonstrate	VB	(VP*	-	-	-	-	*	-
en_5171.txt	0	10	the	DT	(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	11	effectiveness	NN	*)	-	-	-	-	*	-
en_5171.txt	0	12	of	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	13	a	DT	(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	14	treatment	NN	*)	-	-	-	-	*	-
en_5171.txt	0	15	-LRB-	-LRB-	(PRN*	-	-	-	-	*	-
en_5171.txt	0	16	drug	NN	(NP*	-	-	-	-	*	-
en_5171.txt	0	17	,	,	*	-	-	-	-	*	-
en_5171.txt	0	18	medical	JJ	(NX(NX*	-	-	-	-	*	-
en_5171.txt	0	19	device	NN	*)	-	-	-	-	*	-
en_5171.txt	0	20	,	,	*	-	-	-	-	*	-
en_5171.txt	0	21	or	CC	*	-	-	-	-	*	-
en_5171.txt	0	22	other	JJ	(NX*	-	-	-	-	*	-
en_5171.txt	0	23	intervention	NN	*)))	-	-	-	-	*	-
en_5171.txt	0	24	-RRB-	-RRB-	*))))	-	-	-	-	*	-
en_5171.txt	0	25	in	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	26	a	DT	(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	27	completely	RB	(ADJP*	-	-	-	-	*	-
en_5171.txt	0	28	random	JJ	*)	-	-	-	-	*	-
en_5171.txt	0	29	sample	NN	*)	-	-	-	-	*	-
en_5171.txt	0	30	from	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	31	the	DT	(NP*	-	-	-	-	*	(2
en_5171.txt	0	32	general	JJ	*	-	-	-	-	*	-
en_5171.txt	0	33	population	NN	*)))))))))	-	-	-	-	*	2)
en_5171.txt	0	34	.	.	*))	-	-	-	-	*	-

en_5171.txt	0	0	Rather	RB	(TOP(S(ADVP*)	-	-	-	-	*	-
en_5171.txt	0	1	,	,	*	-	-	-	-	*	-
en_5171.txt	0	2	researchers	NNS	(NP*)	-	-	-	-	*	-
en_5171.txt	0	3	``	``	(VP*	-	-	-	-	*	-
en_5171.txt	0	4	enrich	VBP	*	-	-	-	-	*	-
en_5171.txt	0	5	''	''	*	-	-	-	-	*	-
en_5171.txt	0	6	the	DT	(NP*	-	-	-	-	*	(2
en_5171.txt	0	7	study	NN	*	-	-	-	-	*	-
en_5171.txt	0	8	population	NN	*)	-	-	-	-	*	2)
en_5171.txt	0	9	by	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	10	using	VBG	(S(VP*	-	-	-	-	*	-
en_5171.txt	0	11	a	DT	(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	12	characteristic	NN	*)	-	-	-	-	*	-
en_5171.txt	0	13	,	,	*	-	-	-	-	*	-
en_5171.txt	0	14	such	JJ	(PP*	-	-	-	-	*	-
en_5171.txt	0	15	as	IN	*	-	-	-	-	*	-
en_5171.txt	0	16	age	NN	(NP(NP*)	-	-	-	-	*	-
en_5171.txt	0	17	or	CC	*	-	-	-	-	*	-
en_5171.txt	0	18	laboratory-test	JJ	(NP*	-	-	-	-	*	-
en_5171.txt	0	19	results	NNS	*)))	-	-	-	-	*	-
en_5171.txt	0	20	,	,	*)	-	-	-	-	*	-
en_5171.txt	0	21	to	TO	(S(VP*	-	-	-	-	*	-
en_5171.txt	0	22	select	VB	(VP*	-	-	-	-	*	-
en_5171.txt	0	23	a	DT	(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	24	subset	NN	*)	-	-	-	-	*	-
en_5171.txt	0	25	of	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	26	patients	NNS	(NP(NP*)	-	-	-	-	*	-
en_5171.txt	0	27	in	IN	(SBAR(WHPP*	-	-	-	-	*	-
en_5171.txt	0	28	whom	WP	(WHNP*))	-	-	-	-	*	-
en_5171.txt	0	29	the	DT	(S(NP(NP*	-	-	-	-	*	(3|(4
en_5171.txt	0	30	intervention	NN	*	-	-	-	-	*	-
en_5171.txt	0	31	'	POS	*)	-	-	-	-	*	3)
en_5171.txt	0	32	s	JJ	*	-	-	-	-	*	-
en_5171.txt	0	33	effects	NNS	*)	-	-	-	-	*	4)
en_5171.txt	0	34	will	MD	(VP*	-	-	-	-	*	-
en_5171.txt	0	35	likely	RB	(ADVP*)	-	-	-	-	*	-
en_5171.txt	0	36	be	VB	(VP*	-	-	-	-	*	-
en_5171.txt	0	37	easier	JJR	(ADJP(ADJP*	-	-	-	-	*	-
en_5171.txt	0	38	to	TO	(SBAR(S(VP*	-	-	-	-	*	-
en_5171.txt	0	39	detect	VB	(VP*)))))	-	-	-	-	*	-
en_5171.txt	0	40	than	IN	(SBAR*	-	-	-	-	*	-
en_5171.txt	0	41	they	PRP	(S(NP*)	-	-	-	-	*	(4)
en_5171.txt	0	42	would	MD	(VP*	-	-	-	-	*	-
en_5171.txt	0	43	be	VB	(VP*	-	-	-	-	*	-
en_5171.txt	0	44	in	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	45	an	DT	(NP*	-	-	-	-	*	-
en_5171.txt	0	46	unfiltered	JJ	*	-	-	-	-	*	-
en_5171.txt	0	47	population	NN	*)))))))))))))))))))))	-	-	-	-	*	-
en_5171.txt	0	48	.	.	*))	-	-	-	-	*	-

en_5171.txt	0	0	In	IN	(TOP(S(PP*	-	-	-	-	*	-
en_5171.txt	0	1	recent	JJ	(NP*	-	-	-	-	*	-
en_5171.txt	0	2	years	NNS	*))	-	-	-	-	*	-
en_5171.txt	0	3	,	,	*	-	-	-	-	*	-
en_5171.txt	0	4	``	``	(NP*	-	-	-	-	*	-
en_5171.txt	0	5	biomarkers	NNS	(NP*)	-	-	-	-	*	-
en_5171.txt	0	6	,	,	*	-	-	-	-	*	-
en_5171.txt	0	7	''	''	*	-	-	-	-	*	-
en_5171.txt	0	8	such	JJ	(PP*	-	-	-	-	*	-
en_5171.txt	0	9	as	IN	*	-	-	-	-	*	-
en_5171.txt	0	10	certain	JJ	(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	11	DNA	NN	*	-	-	-	-	*	-
en_5171.txt	0	12	sequences	NNS	*)	-	-	-	-	*	-
en_5171.txt	0	13	or	CC	*	-	-	-	-	*	-
en_5171.txt	0	14	the	DT	(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	15	presence	NN	*)	-	-	-	-	*	-
en_5171.txt	0	16	of	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	17	a	DT	(NP*	-	-	-	-	*	-
en_5171.txt	0	18	particular	JJ	*	-	-	-	-	*	-
en_5171.txt	0	19	drug	NN	*	-	-	-	-	*	-
en_5171.txt	0	20	receptor	NN	*)))))	-	-	-	-	*	-
en_5171.txt	0	21	,	,	*)	-	-	-	-	*	-
en_5171.txt	0	22	have	VBP	(VP*	-	-	-	-	*	-
en_5171.txt	0	23	become	VBN	(VP*	-	-	-	-	*	-
en_5171.txt	0	24	increasingly	RB	(NP(ADJP*	-	-	-	-	*	-
en_5171.txt	0	25	important	JJ	*)	-	-	-	-	*	-
en_5171.txt	0	26	indicators	NNS	*)	-	-	-	-	*	-
en_5171.txt	0	27	for	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	28	determining	VBG	(S(VP*	-	-	-	-	*	-
en_5171.txt	0	29	eligibility	NN	(NP*)	-	-	-	-	*	-
en_5171.txt	0	30	for	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	31	clinical	JJ	(NP*	-	-	-	-	*	-
en_5171.txt	0	32	trials	NNS	*)))))))	-	-	-	-	*	-
en_5171.txt	0	33	.	.	*))	-	-	-	-	*	-

en_5171.txt	0	0	This	DT	(TOP(S(NP*	-	-	-	-	*	-
en_5171.txt	0	1	approach	NN	*)	-	-	-	-	*	-
en_5171.txt	0	2	is	VBZ	(VP*	-	-	-	-	*	-
en_5171.txt	0	3	not	RB	(ADJP*	-	-	-	-	*	-
en_5171.txt	0	4	new	JJ	*))	-	-	-	-	*	-
en_5171.txt	0	5	.	.	*))	-	-	-	-	*	-

en_5171.txt	0	0	For	IN	(TOP(S(PP*	-	-	-	-	*	-
en_5171.txt	0	1	example	NN	(NP*))	-	-	-	-	*	-
en_5171.txt	0	2	,	,	*	-	-	-	-	*	-
en_5171.txt	0	3	scientists	NNS	(NP*)	-	-	-	-	*	-
en_5171.txt	0	4	have	VBP	(VP*	-	-	-	-	*	-
en_5171.txt	0	5	known	VBN	(VP*	-	-	-	-	*	-
en_5171.txt	0	6	for	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	7	decades	NNS	(NP*))	-	-	-	-	*	-
en_5171.txt	0	8	that	IN	(SBAR*	-	-	-	-	*	-
en_5171.txt	0	9	certain	JJ	(S(NP*	-	-	-	-	*	-
en_5171.txt	0	10	drugs	NNS	*)	-	-	-	-	*	-
en_5171.txt	0	11	can	MD	(VP*	-	-	-	-	*	-
en_5171.txt	0	12	cause	VB	(VP*	-	-	-	-	*	-
en_5171.txt	0	13	severe	JJ	(NP(NP(ADJP*	-	-	-	-	*	-
en_5171.txt	0	14	and	CC	*	-	-	-	-	*	-
en_5171.txt	0	15	precipitous	JJ	*)	-	-	-	-	*	-
en_5171.txt	0	16	anemia	NN	*)	-	-	-	-	*	-
en_5171.txt	0	17	in	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	18	people	NNS	(NP*))	-	-	-	-	*	-
en_5171.txt	0	19	with	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	20	a	DT	(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	21	genetic	JJ	*	-	-	-	-	*	-
en_5171.txt	0	22	deficiency	NN	*)	-	-	-	-	*	-
en_5171.txt	0	23	of	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	24	the	DT	(NP*	-	-	-	-	*	-
en_5171.txt	0	25	enzyme	JJ	*	-	-	-	-	*	-
en_5171.txt	0	26	G6PD	NN	*)))))))))))	-	-	-	-	*	-
en_5171.txt	0	27	.	.	*))	-	-	-	-	*	-

en_5171.txt	0	0	More	RBR	(TOP(S(ADVP*	-	-	-	-	*	-
en_5171.txt	0	1	recently	RB	*)	-	-	-	-	*	-
en_5171.txt	0	2	,	,	*	-	-	-	-	*	-
en_5171.txt	0	3	researchers	NNS	(NP*)	-	-	-	-	*	-
en_5171.txt	0	4	have	VBP	(VP*	-	-	-	-	*	-
en_5171.txt	0	5	learned	VBN	(VP*	-	-	-	-	*	-
en_5171.txt	0	6	that	IN	(SBAR*	-	-	-	-	*	-
en_5171.txt	0	7	certain	JJ	(S(NP*	-	-	-	-	*	-
en_5171.txt	0	8	cancer	NN	*	-	-	-	-	*	-
en_5171.txt	0	9	drugs	NNS	*)	-	-	-	-	*	-
en_5171.txt	0	10	are	VBP	(VP*	-	-	-	-	*	-
en_5171.txt	0	11	ineffective	JJ	(ADJP*	-	-	-	-	*	-
en_5171.txt	0	12	in	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	13	fighting	VBG	(S(VP*	-	-	-	-	*	-
en_5171.txt	0	14	tumors	NNS	(NP(NP*)	-	-	-	-	*	-
en_5171.txt	0	15	containing	VBG	(VP*	-	-	-	-	*	-
en_5171.txt	0	16	the	DT	(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	17	mutated	VBN	*	-	-	-	-	*	-
en_5171.txt	0	18	variant	NN	*)	-	-	-	-	*	-
en_5171.txt	0	19	of	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	20	the	DT	(NP*	-	-	-	-	*	-
en_5171.txt	0	21	gene	NN	*	-	-	-	-	*	-
en_5171.txt	0	22	KRAS	NNS	*))))))))))))))	-	-	-	-	*	-
en_5171.txt	0	23	.	.	*))	-	-	-	-	*	-

en_5171.txt	0	0	Such	JJ	(TOP(S(NP*	-	-	-	-	*	-
en_5171.txt	0	1	discoveries	NNS	*)	-	-	-	-	*	-
en_5171.txt	0	2	have	VBP	(VP*	-	-	-	-	*	-
en_5171.txt	0	3	enhanced	VBN	(VP*	-	-	-	-	*	-
en_5171.txt	0	4	researchers	NNS	(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	5	'	POS	*)	-	-	-	-	*	-
en_5171.txt	0	6	ability	NN	*	-	-	-	-	*	-
en_5171.txt	0	7	to	TO	(S(VP*	-	-	-	-	*	-
en_5171.txt	0	8	enrich	VB	(VP*	-	-	-	-	*	-
en_5171.txt	0	9	study	NN	(NP*	-	-	-	-	*	-
en_5171.txt	0	10	populations	NNS	*)	-	-	-	-	*	-
en_5171.txt	0	11	with	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	12	patients	NNS	(NP(NP*)	-	-	-	-	*	-
en_5171.txt	0	13	who	WP	(SBAR(WHNP*)	-	-	-	-	*	-
en_5171.txt	0	14	are	VBP	(S(VP*	-	-	-	-	*	-
en_5171.txt	0	15	likely	JJ	(ADJP*	-	-	-	-	*	-
en_5171.txt	0	16	to	TO	(S(VP*	-	-	-	-	*	-
en_5171.txt	0	17	benefit	VB	(VP*	-	-	-	-	*	-
en_5171.txt	0	18	from	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	19	the	DT	(NP*	-	-	-	-	*	(5
en_5171.txt	0	20	drug	NN	*)))))))))))))))	-	-	-	-	*	5)
en_5171.txt	0	21	,	,	*	-	-	-	-	*	-
en_5171.txt	0	22	while	IN	(SBAR*	-	-	-	-	*	-
en_5171.txt	0	23	sparing	VBG	(S(VP*	-	-	-	-	*	-
en_5171.txt	0	24	from	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	25	any	DT	(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	26	possible	JJ	*	-	-	-	-	*	-
en_5171.txt	0	27	side	NN	*	-	-	-	-	*	-
en_5171.txt	0	28	effects	NNS	*)	-	-	-	-	*	-
en_5171.txt	0	29	of	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	30	exposure	NN	(NP*))))	-	-	-	-	*	-
en_5171.txt	0	31	those	DT	(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	32	patients	NNS	*)	-	-	-	-	*	-
en_5171.txt	0	33	who	WP	(SBAR(WHNP*)	-	-	-	-	*	-
en_5171.txt	0	34	are	VBP	(S(VP*	-	-	-	-	*	-
en_5171.txt	0	35	unlikely	JJ	(ADJP*	-	-	-	-	*	-
en_5171.txt	0	36	to	TO	(S(VP*	-	-	-	-	*	-
en_5171.txt	0	37	benefit	VB	(VP*)))))))))))))	-	-	-	-	*	-
en_5171.txt	0	38	.	.	*))	-	-	-	-	*	-

en_5171.txt	0	0	Enrichment	NNP	(TOP(S(NP*)	-	-	-	-	*	(6)
en_5171.txt	0	1	thus	RB	(ADVP*)	-	-	-	-	*	-
en_5171.txt	0	2	enables	VBZ	(VP*	-	-	-	-	*	-
en_5171.txt	0	3	researchers	NNS	(S(NP*)	-	-	-	-	*	-
en_5171.txt	0	4	to	TO	(VP*	-	-	-	-	*	-
en_5171.txt	0	5	strengthen	VB	(VP*	-	-	-	-	*	-
en_5171.txt	0	6	clinical	JJ	(NP(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	7	trials	NNS	*	-	-	-	-	*	-
en_5171.txt	0	8	'	POS	*)	-	-	-	-	*	-
en_5171.txt	0	9	``	``	*	-	-	-	-	*	-
en_5171.txt	0	10	statistical	JJ	*	-	-	-	-	*	-
en_5171.txt	0	11	power	NN	*)	-	-	-	-	*	-
en_5171.txt	0	12	,	,	(PRN*	-	-	-	-	*	-
en_5171.txt	0	13	''	''	*	-	-	-	-	*	-
en_5171.txt	0	14	that	DT	(S(NP*)	-	-	-	-	*	-
en_5171.txt	0	15	is	VBZ	(VP*))	-	-	-	-	*	-
en_5171.txt	0	16	,	,	*)	-	-	-	-	*	-
en_5171.txt	0	17	the	DT	(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	18	probability	NN	*)	-	-	-	-	*	-
en_5171.txt	0	19	of	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	20	detecting	VBG	(S(VP*	-	-	-	-	*	-
en_5171.txt	0	21	differences	NNS	(NP(NP*)	-	-	-	-	*	-
en_5171.txt	0	22	,	,	(PRN*	-	-	-	-	*	-
en_5171.txt	0	23	if	IN	(SBAR*	-	-	-	-	*	-
en_5171.txt	0	24	any	DT	(S(NP*)	-	-	-	-	*	-
en_5171.txt	0	25	exist	VBP	(VP*)))	-	-	-	-	*	-
en_5171.txt	0	26	,	,	*)	-	-	-	-	*	-
en_5171.txt	0	27	between	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	28	study	NN	(NP*	-	-	-	-	*	-
en_5171.txt	0	29	groups	NNS	*))))))))))))	-	-	-	-	*	-
en_5171.txt	0	30	.	.	*))	-	-	-	-	*	-

en_5171.txt	0	0	Given	VBN	(TOP(S(S(VP*	-	-	-	-	*	-
en_5171.txt	0	1	that	IN	(SBAR*	-	-	-	-	*	-
en_5171.txt	0	2	a	DT	(S(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	3	larger	JJR	*	-	-	-	-	*	-
en_5171.txt	0	4	number	NN	*)	-	-	-	-	*	-
en_5171.txt	0	5	of	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	6	subjects	NNS	(NP*	-	-	-	-	*	-
en_5171.txt	0	7	or	CC	*	-	-	-	-	*	-
en_5171.txt	0	8	iterations	NNS	*)))	-	-	-	-	*	-
en_5171.txt	0	9	enhances	VBZ	(VP*	-	-	-	-	*	-
en_5171.txt	0	10	an	DT	(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	11	experiment	NN	*	-	-	-	-	*	-
en_5171.txt	0	12	'	POS	*)	-	-	-	-	*	-
en_5171.txt	0	13	s	JJ	*	-	-	-	-	*	-
en_5171.txt	0	14	ability	NN	*	-	-	-	-	*	-
en_5171.txt	0	15	to	TO	(S(VP*	-	-	-	-	*	-
en_5171.txt	0	16	detect	VB	(VP*	-	-	-	-	*	-
en_5171.txt	0	17	all	DT	(NP(NP*)	-	-	-	-	*	-
en_5171.txt	0	18	of	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	19	the	DT	(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	20	relevant	JJ	*	-	-	-	-	*	-
en_5171.txt	0	21	effects	NNS	*)	-	-	-	-	*	-
en_5171.txt	0	22	,	,	*	-	-	-	-	*	-
en_5171.txt	0	23	which	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_5171.txt	0	24	bolsters	VBZ	(S(VP*	-	-	-	-	*	-
en_5171.txt	0	25	confidence	NN	(NP(NP*)	-	-	-	-	*	-
en_5171.txt	0	26	in	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	27	the	DT	(NP*	-	-	-	-	*	-
en_5171.txt	0	28	result	NN	*))))))))))))))))))	-	-	-	-	*	-
en_5171.txt	0	29	,	,	*	-	-	-	-	*	-
en_5171.txt	0	30	outcomes	NNS	(NP(NP*)	-	-	-	-	*	-
en_5171.txt	0	31	of	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	32	small	JJ	(NP*	-	-	-	-	*	-
en_5171.txt	0	33	studies	NNS	*)))	-	-	-	-	*	-
en_5171.txt	0	34	tend	VBP	(VP*	-	-	-	-	*	-
en_5171.txt	0	35	to	TO	(S(VP*	-	-	-	-	*	-
en_5171.txt	0	36	imply	VB	(VP*	-	-	-	-	*	-
en_5171.txt	0	37	significant	JJ	(NP*	-	-	-	-	*	-
en_5171.txt	0	38	uncertainty	NN	*)	-	-	-	-	*	-
en_5171.txt	0	39	–	SYM	(X*))))	-	-	-	-	*	-
en_5171.txt	0	40	unless	IN	(SBAR*	-	-	-	-	*	-
en_5171.txt	0	41	the	DT	(S(NP(NP*	-	-	-	-	*	(3|(4
en_5171.txt	0	42	intervention	NN	*	-	-	-	-	*	-
en_5171.txt	0	43	'	POS	*)	-	-	-	-	*	3)
en_5171.txt	0	44	s	JJ	*	-	-	-	-	*	-
en_5171.txt	0	45	effects	NNS	*)	-	-	-	-	*	4)
en_5171.txt	0	46	are	VBP	(VP*	-	-	-	-	*	-
en_5171.txt	0	47	potent	JJ	(ADJP*)))))	-	-	-	-	*	-
en_5171.txt	0	48	.	.	*))	-	-	-	-	*	-

en_5171.txt	0	0	Enrichment	NNP	(TOP(S(NP*)	-	-	-	-	*	(6)
en_5171.txt	0	1	allows	VBZ	(VP*	-	-	-	-	*	-
en_5171.txt	0	2	researchers	NNS	(S(NP*)	-	-	-	-	*	(7)
en_5171.txt	0	3	to	TO	(VP*	-	-	-	-	*	-
en_5171.txt	0	4	perform	VB	(VP*	-	-	-	-	*	-
en_5171.txt	0	5	smaller	JJR	(NP(ADJP*	-	-	-	-	*	-
en_5171.txt	0	6	,	,	*	-	-	-	-	*	-
en_5171.txt	0	7	more	JJR	*)	-	-	-	-	*	-
en_5171.txt	0	8	informative	JJ	*	-	-	-	-	*	-
en_5171.txt	0	9	trials	NNS	*)	-	-	-	-	*	-
en_5171.txt	0	10	by	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	11	helping	VBG	(S(VP*	-	-	-	-	*	-
en_5171.txt	0	12	them	PRP	(S(NP*)	-	-	-	-	*	(7)
en_5171.txt	0	13	to	TO	(VP*	-	-	-	-	*	-
en_5171.txt	0	14	design	VB	(VP*	-	-	-	-	*	-
en_5171.txt	0	15	studies	NNS	(NP(NP*)	-	-	-	-	*	-
en_5171.txt	0	16	that	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_5171.txt	0	17	will	MD	(S(VP*	-	-	-	-	*	-
en_5171.txt	0	18	show	VB	(VP*	-	-	-	-	*	-
en_5171.txt	0	19	a	DT	(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	20	high	JJ	*	-	-	-	-	*	-
en_5171.txt	0	21	``	``	*	-	-	-	-	*	-
en_5171.txt	0	22	relative	JJ	*	-	-	-	-	*	-
en_5171.txt	0	23	treatment	NN	*	-	-	-	-	*	-
en_5171.txt	0	24	difference	NN	*	-	-	-	-	*	-
en_5171.txt	0	25	''	''	*)	-	-	-	-	*	-
en_5171.txt	0	26	between	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	27	the	DT	(NP(NP*	-	-	-	-	*	(5
en_5171.txt	0	28	drug	NN	*)	-	-	-	-	*	5)
en_5171.txt	0	29	and	CC	*	-	-	-	-	*	-
en_5171.txt	0	30	whatever	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_5171.txt	0	31	it	PRP	(S(NP*)	-	-	-	-	*	(5)
en_5171.txt	0	32	is	VBZ	(VP*	-	-	-	-	*	-
en_5171.txt	0	33	being	VBG	(VP*	-	-	-	-	*	-
en_5171.txt	0	34	compared	VBN	(VP*	-	-	-	-	*	-
en_5171.txt	0	35	to	TO	(S(VP*))))))))))))	-	-	-	-	*	-
en_5171.txt	0	36	-LRB-	-LRB-	(PRN*	-	-	-	-	*	-
en_5171.txt	0	37	often	RB	(ADVP*)	-	-	-	-	*	-
en_5171.txt	0	38	a	DT	(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	39	placebo	NN	*)	-	-	-	-	*	-
en_5171.txt	0	40	,	,	*	-	-	-	-	*	-
en_5171.txt	0	41	but	CC	(CONJP*	-	-	-	-	*	-
en_5171.txt	0	42	sometimes	RB	*)	-	-	-	-	*	-
en_5171.txt	0	43	another	DT	(NP*	-	-	-	-	*	-
en_5171.txt	0	44	treatment	NN	*))	-	-	-	-	*	-
en_5171.txt	0	45	-RRB-	-RRB-	*))))))))))))))	-	-	-	-	*	-
en_5171.txt	0	46	.	.	*))	-	-	-	-	*	-

en_5171.txt	0	0	In	IN	(TOP(S(PP*	-	-	-	-	*	-
en_5171.txt	0	1	the	DT	(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	2	1980	CD	*	-	-	-	-	*	-
en_5171.txt	0	3	'	POS	*)	-	-	-	-	*	-
en_5171.txt	0	4	s	NN	*))	-	-	-	-	*	-
en_5171.txt	0	5	,	,	*	-	-	-	-	*	-
en_5171.txt	0	6	a	DT	(NP*	-	-	-	-	*	(8
en_5171.txt	0	7	biomarker	NN	*)	-	-	-	-	*	8)
en_5171.txt	0	8	contributed	VBD	(VP*	-	-	-	-	*	-
en_5171.txt	0	9	to	TO	(PP*	-	-	-	-	*	-
en_5171.txt	0	10	the	DT	(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	11	success	NN	*)	-	-	-	-	*	-
en_5171.txt	0	12	of	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	13	the	DT	(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	14	small	JJ	(ADJP*	-	-	-	-	*	-
en_5171.txt	0	15	but	CC	*	-	-	-	-	*	-
en_5171.txt	0	16	seminal	JJ	*)	-	-	-	-	*	-
en_5171.txt	0	17	clinical	JJ	*	-	-	-	-	*	-
en_5171.txt	0	18	trial	NN	*)	-	-	-	-	*	-
en_5171.txt	0	19	of	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	20	human	JJ	(NP*	-	-	-	-	*	-
en_5171.txt	0	21	growth	NN	*	-	-	-	-	*	-
en_5171.txt	0	22	hormone	NN	*))))))	-	-	-	-	*	-
en_5171.txt	0	23	in	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	24	children	NNS	(NP(NP*)	-	-	-	-	*	-
en_5171.txt	0	25	who	WP	(SBAR(WHNP*)	-	-	-	-	*	-
en_5171.txt	0	26	were	VBD	(S(VP*	-	-	-	-	*	-
en_5171.txt	0	27	unable	JJ	(ADJP*	-	-	-	-	*	-
en_5171.txt	0	28	to	TO	(S(VP*	-	-	-	-	*	-
en_5171.txt	0	29	produce	VB	(VP*	-	-	-	-	*	-
en_5171.txt	0	30	it	PRP	(NP*)	-	-	-	-	*	(8)
en_5171.txt	0	31	naturally	RB	(ADVP*)))))))))))	-	-	-	-	*	-
en_5171.txt	0	32	.	.	*))	-	-	-	-	*	-

en_5171.txt	0	0	Some	DT	(TOP(S(S(NP*	-	-	-	-	*	(9
en_5171.txt	0	1	children	NNS	*)	-	-	-	-	*	9)
en_5171.txt	0	2	lose	VBP	(VP*	-	-	-	-	*	-
en_5171.txt	0	3	the	DT	(NP*	-	-	-	-	*	-
en_5171.txt	0	4	ability	NN	*	-	-	-	-	*	-
en_5171.txt	0	5	to	TO	(S(VP*	-	-	-	-	*	-
en_5171.txt	0	6	make	VB	(VP*	-	-	-	-	*	-
en_5171.txt	0	7	growth	NN	(S(NP*	-	-	-	-	*	(10
en_5171.txt	0	8	hormone	NN	*)	-	-	-	-	*	10)
en_5171.txt	0	9	due	JJ	(ADJP*	-	-	-	-	*	-
en_5171.txt	0	10	to	TO	(PP*	-	-	-	-	*	-
en_5171.txt	0	11	injury	NN	(NP*	-	-	-	-	*	-
en_5171.txt	0	12	or	CC	*	-	-	-	-	*	-
en_5171.txt	0	13	tumors	NNS	*))))))))))	-	-	-	-	*	-
en_5171.txt	0	14	;	:	*	-	-	-	-	*	-
en_5171.txt	0	15	others	NNS	(S(NP*)	-	-	-	-	*	-
en_5171.txt	0	16	lack	VBP	(VP*	-	-	-	-	*	-
en_5171.txt	0	17	normal	JJ	(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	18	growth-hormone	JJ	*	-	-	-	-	*	-
en_5171.txt	0	19	activity	NN	*)	-	-	-	-	*	-
en_5171.txt	0	20	from	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	21	birth	NN	(NP*)))	-	-	-	-	*	-
en_5171.txt	0	22	,	,	*	-	-	-	-	*	-
en_5171.txt	0	23	owing	VBG	(S(VP*	-	-	-	-	*	-
en_5171.txt	0	24	to	TO	(PP*	-	-	-	-	*	-
en_5171.txt	0	25	a	DT	(NP*	-	-	-	-	*	-
en_5171.txt	0	26	genetic	JJ	*	-	-	-	-	*	-
en_5171.txt	0	27	mutation	NN	*))))))	-	-	-	-	*	-
en_5171.txt	0	28	;	:	*	-	-	-	-	*	-
en_5171.txt	0	29	and	CC	*	-	-	-	-	*	-
en_5171.txt	0	30	others	NNS	(S(NP*)	-	-	-	-	*	-
en_5171.txt	0	31	are	VBP	(VP*	-	-	-	-	*	-
en_5171.txt	0	32	missing	VBG	(VP*	-	-	-	-	*	-
en_5171.txt	0	33	the	DT	(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	34	gene	NN	*)	-	-	-	-	*	-
en_5171.txt	0	35	that	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_5171.txt	0	36	codes	NNS	(S(VP*	-	-	-	-	*	-
en_5171.txt	0	37	for	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	38	the	DT	(NP*	-	-	-	-	*	(10
en_5171.txt	0	39	hormone	NN	*))	-	-	-	-	*	10)
en_5171.txt	0	40	altogether	RB	(ADVP*))))))))	-	-	-	-	*	-
en_5171.txt	0	41	.	.	*))	-	-	-	-	*	-

en_5171.txt	0	0	Giving	VBG	(TOP(S(S(VP*	-	-	-	-	*	-
en_5171.txt	0	1	the	DT	(SBAR(S(NP*	-	-	-	-	*	(10
en_5171.txt	0	2	latter	JJ	*	-	-	-	-	*	-
en_5171.txt	0	3	group	NN	*	-	-	-	-	*	-
en_5171.txt	0	4	exogenous	NN	*	-	-	-	-	*	-
en_5171.txt	0	5	growth	NN	*	-	-	-	-	*	-
en_5171.txt	0	6	hormone	NN	*)	-	-	-	-	*	10)
en_5171.txt	0	7	is	VBZ	(VP*	-	-	-	-	*	-
en_5171.txt	0	8	futile	JJ	(ADJP*)	-	-	-	-	*	-
en_5171.txt	0	9	,	,	*	-	-	-	-	*	-
en_5171.txt	0	10	because	IN	(SBAR*	-	-	-	-	*	-
en_5171.txt	0	11	their	PRP$	(S(NP*	-	-	-	-	*	(9)
en_5171.txt	0	12	immune	JJ	*	-	-	-	-	*	-
en_5171.txt	0	13	systems	NNS	*)	-	-	-	-	*	-
en_5171.txt	0	14	react	VBP	(VP*	-	-	-	-	*	-
en_5171.txt	0	15	to	TO	(PP*	-	-	-	-	*	-
en_5171.txt	0	16	the	DT	(NP*	-	-	-	-	*	-
en_5171.txt	0	17	``	``	*	-	-	-	-	*	-
en_5171.txt	0	18	foreign	JJ	*	-	-	-	-	*	-
en_5171.txt	0	19	''	''	*	-	-	-	-	*	-
en_5171.txt	0	20	protein	NN	*))	-	-	-	-	*	-
en_5171.txt	0	21	by	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	22	producing	VBG	(S(VP*	-	-	-	-	*	-
en_5171.txt	0	23	antibodies	NNS	(NP*)))))))))	-	-	-	-	*	-
en_5171.txt	0	24	.	.	*	-	-	-	-	*	-
en_5171.txt	0	25	Although	IN	(SBAR*	-	-	-	-	*	-
en_5171.txt	0	26	the	DT	(S(NP*	-	-	-	-	*	(10
en_5171.txt	0	27	hormone	NN	*)	-	-	-	-	*	10)
en_5171.txt	0	28	may	MD	(VP*	-	-	-	-	*	-
en_5171.txt	0	29	stimulate	VB	(VP*	-	-	-	-	*	-
en_5171.txt	0	30	growth	NN	(NP*)	-	-	-	-	*	-
en_5171.txt	0	31	for	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	32	a	DT	(NP*	-	-	-	-	*	-
en_5171.txt	0	33	short	JJ	*	-	-	-	-	*	-
en_5171.txt	0	34	period	NN	*)))))))))	-	-	-	-	*	-
en_5171.txt	0	35	,	,	*	-	-	-	-	*	-
en_5171.txt	0	36	the	DT	(NP*	-	-	-	-	*	-
en_5171.txt	0	37	antibodies	NNS	*)	-	-	-	-	*	-
en_5171.txt	0	38	soon	RB	(VP(VP(ADVP*)	-	-	-	-	*	-
en_5171.txt	0	39	bind	VBD	*)	-	-	-	-	*	-
en_5171.txt	0	40	and	CC	*	-	-	-	-	*	-
en_5171.txt	0	41	neutralize	VB	(VP*	-	-	-	-	*	-
en_5171.txt	0	42	it	PRP	(NP*)))	-	-	-	-	*	(10)
en_5171.txt	0	43	.	.	*))	-	-	-	-	*	-

en_5171.txt	0	0	By	IN	(TOP(S(PP*	-	-	-	-	*	-
en_5171.txt	0	1	limiting	VBG	(S(VP*	-	-	-	-	*	-
en_5171.txt	0	2	the	DT	(NP*	-	-	-	-	*	(2
en_5171.txt	0	3	study	NN	*	-	-	-	-	*	-
en_5171.txt	0	4	population	NN	*)	-	-	-	-	*	2)
en_5171.txt	0	5	to	TO	(PP*	-	-	-	-	*	-
en_5171.txt	0	6	children	NNS	(NP(NP*)	-	-	-	-	*	-
en_5171.txt	0	7	in	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	8	the	DT	(NP*	-	-	-	-	*	-
en_5171.txt	0	9	other	JJ	*	-	-	-	-	*	-
en_5171.txt	0	10	two	CD	*	-	-	-	-	*	-
en_5171.txt	0	11	groups	NNS	*))	-	-	-	-	*	-
en_5171.txt	0	12	,	,	*	-	-	-	-	*	-
en_5171.txt	0	13	for	IN	(SBAR(WHPP*	-	-	-	-	*	-
en_5171.txt	0	14	whom	WP	(WHNP*))	-	-	-	-	*	-
en_5171.txt	0	15	exogenous	JJ	(S(NP*	-	-	-	-	*	-
en_5171.txt	0	16	growth	NN	*	-	-	-	-	*	-
en_5171.txt	0	17	hormone	NN	*)	-	-	-	-	*	-
en_5171.txt	0	18	stimulates	VBZ	(VP*	-	-	-	-	*	-
en_5171.txt	0	19	normal	JJ	(NP*	-	-	-	-	*	-
en_5171.txt	0	20	growth	NN	*)))))))))	-	-	-	-	*	-
en_5171.txt	0	21	,	,	*	-	-	-	-	*	-
en_5171.txt	0	22	researchers	NNS	(NP*)	-	-	-	-	*	-
en_5171.txt	0	23	achieved	VBD	(VP*	-	-	-	-	*	-
en_5171.txt	0	24	a	DT	(NP*	-	-	-	-	*	-
en_5171.txt	0	25	100	CD	(ADJP*	-	-	-	-	*	-
en_5171.txt	0	26	%	NN	*)	-	-	-	-	*	-
en_5171.txt	0	27	relative	JJ	*	-	-	-	-	*	-
en_5171.txt	0	28	treatment	NN	*	-	-	-	-	*	-
en_5171.txt	0	29	difference	NN	*))	-	-	-	-	*	-
en_5171.txt	0	30	.	.	*	-	-	-	-	*	-
en_5171.txt	0	31	In	IN	(S(S(PP*	-	-	-	-	*	-
en_5171.txt	0	32	other	JJ	(NP*	-	-	-	-	*	-
en_5171.txt	0	33	words	NNS	*))	-	-	-	-	*	-
en_5171.txt	0	34	,	,	*	-	-	-	-	*	-
en_5171.txt	0	35	every	DT	(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	36	subject	NN	*)	-	-	-	-	*	-
en_5171.txt	0	37	who	WP	(SBAR(WHNP*)	-	-	-	-	*	-
en_5171.txt	0	38	received	VBD	(S(VP*	-	-	-	-	*	-
en_5171.txt	0	39	the	DT	(NP*	-	-	-	-	*	(5
en_5171.txt	0	40	active	JJ	*	-	-	-	-	*	-
en_5171.txt	0	41	drug	NN	*)))))	-	-	-	-	*	5)
en_5171.txt	0	42	responded	VBD	(VP*))	-	-	-	-	*	-
en_5171.txt	0	43	,	,	*	-	-	-	-	*	-
en_5171.txt	0	44	and	CC	*	-	-	-	-	*	-
en_5171.txt	0	45	none	NN	(S(NP(NP*)	-	-	-	-	*	-
en_5171.txt	0	46	of	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	47	those	DT	(NP(NP*)	-	-	-	-	*	-
en_5171.txt	0	48	who	WP	(SBAR(WHNP*)	-	-	-	-	*	-
en_5171.txt	0	49	received	VBD	(S(VP*	-	-	-	-	*	-
en_5171.txt	0	50	the	DT	(NP*	-	-	-	-	*	-
en_5171.txt	0	51	placebo	NN	*)))))))	-	-	-	-	*	-
en_5171.txt	0	52	did	VBD	(VP*)))	-	-	-	-	*	-
en_5171.txt	0	53	.	.	*))	-	-	-	-	*	-

en_5171.txt	0	0	Clearly	RB	(TOP(S(ADVP*)	-	-	-	-	*	-
en_5171.txt	0	1	,	,	*	-	-	-	-	*	-
en_5171.txt	0	2	genetic	JJ	(NP*	-	-	-	-	*	-
en_5171.txt	0	3	markers	NNS	*)	-	-	-	-	*	-
en_5171.txt	0	4	are	VBP	(VP*	-	-	-	-	*	-
en_5171.txt	0	5	useful	JJ	(ADJP*	-	-	-	-	*	-
en_5171.txt	0	6	in	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	7	designing	VBG	(S(VP*	-	-	-	-	*	-
en_5171.txt	0	8	clinical	JJ	(NP*	-	-	-	-	*	-
en_5171.txt	0	9	trials	NNS	*))))))	-	-	-	-	*	-
en_5171.txt	0	10	.	.	*))	-	-	-	-	*	-

en_5171.txt	0	0	But	CC	(TOP(SBARQ*	-	-	-	-	*	-
en_5171.txt	0	1	are	VBP	(SQ*	-	-	-	-	*	-
en_5171.txt	0	2	more	RBR	(NP(NP(ADJP*	-	-	-	-	*	-
en_5171.txt	0	3	subjective	JJ	*)	-	-	-	-	*	-
en_5171.txt	0	4	factors	NNS	*)	-	-	-	-	*	-
en_5171.txt	0	5	like	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	6	race	NN	(NP*	-	-	-	-	*	-
en_5171.txt	0	7	or	CC	*	-	-	-	-	*	-
en_5171.txt	0	8	ethnicity	NN	*)))	-	-	-	-	*	-
en_5171.txt	0	9	also	RB	(ADVP*)	-	-	-	-	*	-
en_5171.txt	0	10	relevant	JJ	(ADJP*))	-	-	-	-	*	-
en_5171.txt	0	11	?	.	*))	-	-	-	-	*	-

en_5171.txt	0	0	For	IN	(TOP(S(PP*	-	-	-	-	*	-
en_5171.txt	0	1	the	DT	(NP(NP*	-	-	-	-	*	(11
en_5171.txt	0	2	cardiac	JJ	*	-	-	-	-	*	-
en_5171.txt	0	3	drug	NN	*	-	-	-	-	*	-
en_5171.txt	0	4	BiDil	NNP	*)	-	-	-	-	*	-
en_5171.txt	0	5	-LRB-	-LRB-	(PRN*	-	-	-	-	*	-
en_5171.txt	0	6	a	DT	(NP(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	7	combination	NN	*)	-	-	-	-	*	-
en_5171.txt	0	8	of	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	9	the	DT	(NP*	-	-	-	-	*	-
en_5171.txt	0	10	vasodilators	NNS	*	-	-	-	-	*	-
en_5171.txt	0	11	hydralazine	NN	*)))	-	-	-	-	*	-
en_5171.txt	0	12	and	CC	*	-	-	-	-	*	-
en_5171.txt	0	13	isosorbide	JJ	(NP*	-	-	-	-	*	-
en_5171.txt	0	14	dinitrate	NN	*))	-	-	-	-	*	-
en_5171.txt	0	15	-RRB-	-RRB-	*)))	-	-	-	-	*	11)
en_5171.txt	0	16	,	,	*	-	-	-	-	*	-
en_5171.txt	0	17	the	DT	(NP*	-	-	-	-	*	-
en_5171.txt	0	18	answer	NN	*)	-	-	-	-	*	-
en_5171.txt	0	19	is	VBZ	(VP*	-	-	-	-	*	-
en_5171.txt	0	20	yes	RB	(ADVP*))	-	-	-	-	*	-
en_5171.txt	0	21	.	.	*))	-	-	-	-	*	-

en_5171.txt	0	0	In	IN	(TOP(S(PP*	-	-	-	-	*	-
en_5171.txt	0	1	1996	CD	(NP*))	-	-	-	-	*	-
en_5171.txt	0	2	,	,	*	-	-	-	-	*	-
en_5171.txt	0	3	inconclusive	JJ	(NP*	-	-	-	-	*	-
en_5171.txt	0	4	clinical	JJ	*	-	-	-	-	*	-
en_5171.txt	0	5	trials	NNS	*)	-	-	-	-	*	-
en_5171.txt	0	6	led	VBD	(VP*	-	-	-	-	*	-
en_5171.txt	0	7	US	NNP	(S(NP*	-	-	-	-	*	-
en_5171.txt	0	8	regulators	NNS	*)	-	-	-	-	*	-
en_5171.txt	0	9	to	TO	(VP*	-	-	-	-	*	-
en_5171.txt	0	10	reject	VB	(VP*	-	-	-	-	*	-
en_5171.txt	0	11	the	DT	(NP*	-	-	-	-	*	(5
en_5171.txt	0	12	drug	NN	*)))))	-	-	-	-	*	5)
en_5171.txt	0	13	.	.	*))	-	-	-	-	*	-

en_5171.txt	0	0	But	CC	(TOP(S*	-	-	-	-	*	-
en_5171.txt	0	1	when	WRB	(SBAR(WHADVP*)	-	-	-	-	*	-
en_5171.txt	0	2	more	RBR	(S(NP(NP(ADJP*	-	-	-	-	*	-
en_5171.txt	0	3	detailed	JJ	*)	-	-	-	-	*	-
en_5171.txt	0	4	analysis	NN	*)	-	-	-	-	*	-
en_5171.txt	0	5	of	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	6	the	DT	(NP*	-	-	-	-	*	(1
en_5171.txt	0	7	data	NNS	*)))	-	-	-	-	*	1)
en_5171.txt	0	8	revealed	VBD	(VP*	-	-	-	-	*	-
en_5171.txt	0	9	potentially	RB	(NP(NP(ADJP*	-	-	-	-	*	-
en_5171.txt	0	10	elevated	JJ	*)	-	-	-	-	*	-
en_5171.txt	0	11	benefits	NNS	*)	-	-	-	-	*	-
en_5171.txt	0	12	for	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	13	black	JJ	(NP*	-	-	-	-	*	-
en_5171.txt	0	14	patients	NNS	*))))))	-	-	-	-	*	-
en_5171.txt	0	15	,	,	*	-	-	-	-	*	-
en_5171.txt	0	16	a	DT	(NP*	-	-	-	-	*	-
en_5171.txt	0	17	new	JJ	*	-	-	-	-	*	-
en_5171.txt	0	18	trial	NN	*)	-	-	-	-	*	-
en_5171.txt	0	19	was	VBD	(VP*	-	-	-	-	*	-
en_5171.txt	0	20	performed	VBN	(VP*	-	-	-	-	*	-
en_5171.txt	0	21	on	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	22	1,050	CD	(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	23	self-identified	JJ	*	-	-	-	-	*	-
en_5171.txt	0	24	``	``	*	-	-	-	-	*	-
en_5171.txt	0	25	black	JJ	*	-	-	-	-	*	-
en_5171.txt	0	26	''	''	*	-	-	-	-	*	-
en_5171.txt	0	27	patients	NNS	*)	-	-	-	-	*	-
en_5171.txt	0	28	with	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	29	severe	JJ	(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	30	heart	NN	*	-	-	-	-	*	-
en_5171.txt	0	31	failure	NN	*)	-	-	-	-	*	-
en_5171.txt	0	32	for	IN	(SBAR(WHPP*	-	-	-	-	*	-
en_5171.txt	0	33	whom	WP	(WHNP*))	-	-	-	-	*	-
en_5171.txt	0	34	available	JJ	(S(NP*	-	-	-	-	*	-
en_5171.txt	0	35	treatments	NNS	*)	-	-	-	-	*	-
en_5171.txt	0	36	had	VBD	(VP*	-	-	-	-	*	-
en_5171.txt	0	37	proved	VBN	(VP*	-	-	-	-	*	-
en_5171.txt	0	38	ineffective	JJ	(ADJP*)))))))))))	-	-	-	-	*	-
en_5171.txt	0	39	.	.	*))	-	-	-	-	*	-

en_5171.txt	0	0	The	DT	(TOP(S(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	1	results	NNS	*)	-	-	-	-	*	-
en_5171.txt	0	2	–	SYM	(PP(X(X*)	-	-	-	-	*	-
en_5171.txt	0	3	a	DT	(NP(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	4	43	CD	(ADJP*	-	-	-	-	*	-
en_5171.txt	0	5	%	NN	*)	-	-	-	-	*	-
en_5171.txt	0	6	reduction	NN	*)	-	-	-	-	*	-
en_5171.txt	0	7	in	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	8	mortality	NN	(NP*)))	-	-	-	-	*	-
en_5171.txt	0	9	and	CC	*	-	-	-	-	*	-
en_5171.txt	0	10	a	DT	(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	11	39	CD	(ADJP*	-	-	-	-	*	-
en_5171.txt	0	12	%	NN	*)	-	-	-	-	*	-
en_5171.txt	0	13	decrease	NN	*)	-	-	-	-	*	-
en_5171.txt	0	14	in	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	15	hospital	NN	(NP*	-	-	-	-	*	-
en_5171.txt	0	16	visits	NNS	*)))))	-	-	-	-	*	-
en_5171.txt	0	17	among	IN	*	-	-	-	-	*	-
en_5171.txt	0	18	patients	NNS	(NP*))	-	-	-	-	*	-
en_5171.txt	0	19	who	WP	(SBAR(WHNP*)	-	-	-	-	*	-
en_5171.txt	0	20	received	VBD	(S(VP*	-	-	-	-	*	-
en_5171.txt	0	21	BiDil	NNP	(NP*)	-	-	-	-	*	(11)
en_5171.txt	0	22	–	SYM	(X*)))))	-	-	-	-	*	-
en_5171.txt	0	23	were	VBD	(VP*	-	-	-	-	*	-
en_5171.txt	0	24	so	RB	(ADJP*	-	-	-	-	*	-
en_5171.txt	0	25	striking	JJ	*	-	-	-	-	*	-
en_5171.txt	0	26	that	IN	(SBAR*	-	-	-	-	*	-
en_5171.txt	0	27	the	DT	(S(NP*	-	-	-	-	*	-
en_5171.txt	0	28	study	NN	*)	-	-	-	-	*	-
en_5171.txt	0	29	was	VBD	(VP*	-	-	-	-	*	-
en_5171.txt	0	30	concluded	VBN	(VP*	-	-	-	-	*	-
en_5171.txt	0	31	early	RB	(ADVP*)))))))	-	-	-	-	*	-
en_5171.txt	0	32	.	.	*))	-	-	-	-	*	-

en_5171.txt	0	0	Although	IN	(TOP(S(SBAR*	-	-	-	-	*	-
en_5171.txt	0	1	BiDil	NNP	(S(NP*)	-	-	-	-	*	(11)
en_5171.txt	0	2	has	VBZ	(VP*	-	-	-	-	*	-
en_5171.txt	0	3	not	RB	*	-	-	-	-	*	-
en_5171.txt	0	4	been	VBN	(VP*	-	-	-	-	*	-
en_5171.txt	0	5	a	DT	(NP*	-	-	-	-	*	-
en_5171.txt	0	6	great	JJ	*	-	-	-	-	*	-
en_5171.txt	0	7	commercial	JJ	*	-	-	-	-	*	-
en_5171.txt	0	8	success	NN	*)	-	-	-	-	*	-
en_5171.txt	0	9	since	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	10	its	PRP$	(NP*	-	-	-	-	*	(11)
en_5171.txt	0	11	approval	NN	*))	-	-	-	-	*	-
en_5171.txt	0	12	in	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	13	2009	CD	(NP*))))))	-	-	-	-	*	-
en_5171.txt	0	14	,	,	*	-	-	-	-	*	-
en_5171.txt	0	15	it	PRP	(NP*)	-	-	-	-	*	(11)
en_5171.txt	0	16	remains	VBZ	(VP*	-	-	-	-	*	-
en_5171.txt	0	17	on	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	18	the	DT	(NP*	-	-	-	-	*	-
en_5171.txt	0	19	market	NN	*)))	-	-	-	-	*	-
en_5171.txt	0	20	.	.	*))	-	-	-	-	*	-

en_5171.txt	0	0	Some	DT	(TOP(S(NP*)	-	-	-	-	*	-
en_5171.txt	0	1	regard	VBP	(VP*	-	-	-	-	*	-
en_5171.txt	0	2	race-based	JJ	(NP*	-	-	-	-	*	-
en_5171.txt	0	3	medical	JJ	*	-	-	-	-	*	-
en_5171.txt	0	4	treatment	NN	*)	-	-	-	-	*	-
en_5171.txt	0	5	as	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	6	necessary	JJ	(ADJP*	-	-	-	-	*	-
en_5171.txt	0	7	to	TO	(S(VP*	-	-	-	-	*	-
en_5171.txt	0	8	reduce	VB	(VP*	-	-	-	-	*	-
en_5171.txt	0	9	health	NN	(NP*	-	-	-	-	*	-
en_5171.txt	0	10	disparities	NNS	*))))))	-	-	-	-	*	-
en_5171.txt	0	11	,	,	*	-	-	-	-	*	-
en_5171.txt	0	12	while	IN	(SBAR*	-	-	-	-	*	-
en_5171.txt	0	13	others	NNS	(S(NP*)	-	-	-	-	*	-
en_5171.txt	0	14	view	VBP	(VP*	-	-	-	-	*	-
en_5171.txt	0	15	it	PRP	(NP*)	-	-	-	-	*	(11)
en_5171.txt	0	16	as	RB	(PP*	-	-	-	-	*	-
en_5171.txt	0	17	downright	RB	(ADJP*	-	-	-	-	*	-
en_5171.txt	0	18	discriminatory	JJ	*))))))	-	-	-	-	*	-
en_5171.txt	0	19	.	.	*))	-	-	-	-	*	-

en_5171.txt	0	0	When	WRB	(TOP(S(SBAR(WHADVP*)	-	-	-	-	*	-
en_5171.txt	0	1	BiDil	NNP	(S(NP*)	-	-	-	-	*	(11)
en_5171.txt	0	2	was	VBD	(VP*	-	-	-	-	*	-
en_5171.txt	0	3	approved	VBN	(VP*))))	-	-	-	-	*	-
en_5171.txt	0	4	,	,	*	-	-	-	-	*	-
en_5171.txt	0	5	Francis	NNP	(NP(NP*	-	-	-	-	*	(12
en_5171.txt	0	6	Collins	NNP	*)	-	-	-	-	*	-
en_5171.txt	0	7	,	,	*	-	-	-	-	*	-
en_5171.txt	0	8	who	WP	(SBAR(WHNP*)	-	-	-	-	*	-
en_5171.txt	0	9	was	VBD	(S(VP*	-	-	-	-	*	-
en_5171.txt	0	10	Director	NNP	(NP(NP*)	-	-	-	-	*	-
en_5171.txt	0	11	of	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	12	the	DT	(NP*	-	-	-	-	*	-
en_5171.txt	0	13	US	NNP	*	-	-	-	-	*	-
en_5171.txt	0	14	National	NNP	*	-	-	-	-	*	-
en_5171.txt	0	15	Human	NNP	*	-	-	-	-	*	-
en_5171.txt	0	16	Genome	NNP	*	-	-	-	-	*	-
en_5171.txt	0	17	Research	NNP	*	-	-	-	-	*	-
en_5171.txt	0	18	Institute	NNP	*)))	-	-	-	-	*	-
en_5171.txt	0	19	at	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	20	the	DT	(NP*	-	-	-	-	*	-
en_5171.txt	0	21	time	NN	*)))))	-	-	-	-	*	-
en_5171.txt	0	22	,	,	*)	-	-	-	-	*	12)
en_5171.txt	0	23	warned	VBD	(VP*	-	-	-	-	*	-
en_5171.txt	0	24	that	IN	(SBAR*	-	-	-	-	*	-
en_5171.txt	0	25	``	``	*	-	-	-	-	*	-
en_5171.txt	0	26	we	PRP	(S(NP*)	-	-	-	-	*	(13)
en_5171.txt	0	27	should	MD	(VP*	-	-	-	-	*	-
en_5171.txt	0	28	move	VB	(VP*	-	-	-	-	*	-
en_5171.txt	0	29	without	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	30	delay	NN	(NP(NP*)	-	-	-	-	*	-
en_5171.txt	0	31	from	IN	(PP(PP*	-	-	-	-	*	-
en_5171.txt	0	32	blurry	JJ	(NP(NP(ADJP*	-	-	-	-	*	-
en_5171.txt	0	33	and	CC	*	-	-	-	-	*	-
en_5171.txt	0	34	potentially	RB	*	-	-	-	-	*	-
en_5171.txt	0	35	misleading	JJ	*)	-	-	-	-	*	-
en_5171.txt	0	36	surrogates	NNS	*)	-	-	-	-	*	-
en_5171.txt	0	37	for	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	38	drug	NN	(NP*	-	-	-	-	*	-
en_5171.txt	0	39	response	NN	*))	-	-	-	-	*	-
en_5171.txt	0	40	,	,	*	-	-	-	-	*	-
en_5171.txt	0	41	such	JJ	(PP*	-	-	-	-	*	-
en_5171.txt	0	42	as	IN	*	-	-	-	-	*	-
en_5171.txt	0	43	race	NN	(NP*))	-	-	-	-	*	-
en_5171.txt	0	44	,	,	*))	-	-	-	-	*	-
en_5171.txt	0	45	to	TO	(PP*	-	-	-	-	*	-
en_5171.txt	0	46	the	DT	(NP*	-	-	-	-	*	-
en_5171.txt	0	47	more	RBR	(ADJP*	-	-	-	-	*	-
en_5171.txt	0	48	specific	JJ	*)	-	-	-	-	*	-
en_5171.txt	0	49	causes	NNS	*))))))))))	-	-	-	-	*	-
en_5171.txt	0	50	.	.	*	-	-	-	-	*	-
en_5171.txt	0	51	''	''	*))	-	-	-	-	*	-

en_5171.txt	0	0	Of	IN	(TOP(S(S(PP*	-	-	-	-	*	-
en_5171.txt	0	1	course	NN	(NP*))	-	-	-	-	*	-
en_5171.txt	0	2	,	,	*	-	-	-	-	*	-
en_5171.txt	0	3	Collins	NNP	(NP*)	-	-	-	-	*	(12)
en_5171.txt	0	4	was	VBD	(VP*	-	-	-	-	*	-
en_5171.txt	0	5	correct	JJ	(ADJP*)))	-	-	-	-	*	-
en_5171.txt	0	6	;	:	*	-	-	-	-	*	-
en_5171.txt	0	7	race	NN	(S(NP*)	-	-	-	-	*	-
en_5171.txt	0	8	is	VBZ	(VP*	-	-	-	-	*	-
en_5171.txt	0	9	a	DT	(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	10	crude	JJ	(ADJP*	-	-	-	-	*	-
en_5171.txt	0	11	and	CC	*	-	-	-	-	*	-
en_5171.txt	0	12	incomplete	JJ	*)	-	-	-	-	*	-
en_5171.txt	0	13	mechanism	NN	*)	-	-	-	-	*	-
en_5171.txt	0	14	for	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	15	understanding	VBG	(NP*	-	-	-	-	*	-
en_5171.txt	0	16	genetic	JJ	*	-	-	-	-	*	-
en_5171.txt	0	17	differences	NNS	*)))))	-	-	-	-	*	-
en_5171.txt	0	18	.	.	*))	-	-	-	-	*	-

en_5171.txt	0	0	But	CC	(TOP(S*	-	-	-	-	*	-
en_5171.txt	0	1	we	PRP	(NP*)	-	-	-	-	*	(13)
en_5171.txt	0	2	must	MD	(VP*	-	-	-	-	*	-
en_5171.txt	0	3	fight	VB	(VP*	-	-	-	-	*	-
en_5171.txt	0	4	illness	NN	(NP*)	-	-	-	-	*	-
en_5171.txt	0	5	with	IN	(PP*	-	-	-	-	*	-
en_5171.txt	0	6	the	DT	(NP(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	7	data	NNS	*)	-	-	-	-	*	-
en_5171.txt	0	8	we	PRP	(SBAR(S(NP*)	-	-	-	-	*	(13)
en_5171.txt	0	9	have	VBP	(VP*))))	-	-	-	-	*	-
en_5171.txt	0	10	,	,	*	-	-	-	-	*	-
en_5171.txt	0	11	not	RB	*	-	-	-	-	*	-
en_5171.txt	0	12	the	DT	(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	13	data	NNS	*)	-	-	-	-	*	-
en_5171.txt	0	14	we	PRP	(SBAR(S(NP*)	-	-	-	-	*	(13)
en_5171.txt	0	15	wish	VBP	(VP*	-	-	-	-	*	-
en_5171.txt	0	16	we	PRP	(SBAR(S(NP*)	-	-	-	-	*	(13)
en_5171.txt	0	17	had	VBD	(VP*)))))))))))	-	-	-	-	*	-
en_5171.txt	0	18	.	.	*))	-	-	-	-	*	-

en_5171.txt	0	0	Political	NNP	(TOP(S(NP(NP*)	-	-	-	-	*	-
en_5171.txt	0	1	and	CC	*	-	-	-	-	*	-
en_5171.txt	0	2	ethical	JJ	(NP(NP(NP*	-	-	-	-	*	-
en_5171.txt	0	3	sensitivities	NNS	*)	-	-	-	-	*	-
en_5171.txt	0	4	notwithstanding	RB	(ADVP*))	-	-	-	-	*	-
en_5171.txt	0	5	,	,	*	-	-	-	-	*	-
en_5171.txt	0	6	drug	NN	(NP*	-	-	-	-	*	-
en_5171.txt	0	7	testing	NN	*)	-	-	-	-	*	-
en_5171.txt	0	8	,	,	*	-	-	-	-	*	-
en_5171.txt	0	9	approval	NN	(NP*)	-	-	-	-	*	-
en_5171.txt	0	10	,	,	*	-	-	-	-	*	-
en_5171.txt	0	11	and	CC	*	-	-	-	-	*	-
en_5171.txt	0	12	labeling	NN	(NP*)))	-	-	-	-	*	-
en_5171.txt	0	13	must	MD	(VP*	-	-	-	-	*	-
en_5171.txt	0	14	go	VB	(VP*	-	-	-	-	*	-
en_5171.txt	0	15	wherever	WRB	(SBAR(WHADVP*)	-	-	-	-	*	-
en_5171.txt	0	16	the	DT	(S(NP*	-	-	-	-	*	-
en_5171.txt	0	17	evidence	NN	*)	-	-	-	-	*	-
en_5171.txt	0	18	leads	VBZ	(VP*)))))	-	-	-	-	*	-
en_5171.txt	0	19	.	.	*))	-	-	-	-	*	-

#end document
